EUVIMEDEUVIMED entdecken
Leserbrief

Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study

Fatima Rajab, Aleena Mujahid, Hadia Rajab, Abdullah Alvi

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.01.187 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Fatima Rajab und 3 weiteren Autor:innen. Beteiligte Einrichtung: King Edward Medical University, Lahore, Pakistan. Electronic address: frajab258@gmail.com. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInflammatory Bowel DiseasesHumansAntibodies, Monoclonal, HumanizedAdministration, IntravenousGastrointestinal AgentsTreatment OutcomeRemission Induction

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • King Edward Medical University, Lahore, Pakistan. Electronic address: frajab258@gmail.com.
  • King Edward Medical University, Lahore, Pakistan.
  • University of Lahore, Lahore, Pakistan.

Zitieren

APA

Rajab, F., Mujahid, A., Rajab, H., & Alvi, A. (2024). Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.01.187

Vancouver

Rajab F, Mujahid A, Rajab H, Alvi A. Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.01.187

BibTeX
@article{Rajab2024,
  author = {Rajab, Fatima and Mujahid, Aleena and Rajab, Hadia and Alvi, Abdullah},
  title = {Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.01.187}
}
Kostenlos starten →